British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update

Sue Wilson1, Kirstie Anderson2, David Baldwin3, Derk-Jan Dijk4, Audrey Espie5, Colin Espie6, Paul Gringras7, Andrew Krystal8, David Nutt1, Hugh Selsick9 and Ann Sharples10

Abstract
This British Association for Psychopharmacology guideline replaces the original version published in 2010, and contains updated information and recommendations. A consensus meeting was held in London in October 2017 attended by recognised experts and advocates in the field. They were asked to provide a review of the literature and identification of the standard of evidence in their area, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. Each presentation was followed by discussion, aiming to reach consensus where the evidence and/or clinical experience was considered adequate, or otherwise to flag the area as a direction for future research. A draft of the proceedings was circulated to all speakers for comments, which were incorporated into the final statement.

Keywords
Sleep disorders, insomnia, circadian rhythm disorders, parasomnias, guidelines, evidence-based treatment

Table of Contents
Introduction 2
Method 2
Insomnia 2
Scope of the guidelines 2
Epidemiology of insomnia 3
Table 1 Levels of evidence 3
Diagnosis of insomnia 4
Table 2 Insomnia: diagnostic criteria 4
Comorbidity 5
Costs and consequences of insomnia 5
Fig 2 The ideal sleeping pill 6
Recommendation 6
Psychological treatment of insomnia 7
Underpinning principles – cognitive behavioural therapy 7
Recommendation 7
Drug treatments for insomnia 7
Underpinning principles - pharmacology 8
Underpinning principles – pharmacokinetics 8
Fig 3 treatment of insomnia 9
Tolerance, dependence and withdrawal 9
Pharmacological treatment of insomnia 10
Recommendations 10
Long-term use of sleeping medications 10
Recommendation 11
Using drugs for depression to treat insomnia 11
Recommendations 12

Drugs for psychosis for treatment of insomnia 12
Recommendations 13
Antihistamines (H1 antagonists) 13
Recommendations 13

Circadian rhythm disorders 13
Diagnosis of circadian rhythm disorders 14
Treating circadian rhythm disorders 14
Recommendations 14

Parasomnias 15
Diagnosis of parasomnias 15
Treatment of parasomnias 15

Special populations 16
Sleep disorders in women: effects of menopause and pregnancy 16
Menopause 16
Recommendations 16
Pregnancy 16
Recommendations 16
Treating insomnia in older adults 17
Recommendation 17
Sleep problems in children 17
Recommendations 18
Sleep disturbance in adults with intellectual disability 18
Assessment 18
Treatment considerations 18
Recommendations 19

References 19
Appendix 1 25
Introduction

Sleep disorders are common in the general population, and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners. These British Association for Psychopharmacology (BAP) guidelines address this problem by providing an accessible yet up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. We limited ourselves to discussion of sleep problems that are not regarded as being secondary to sleep disordered breathing; National Institute of Clinical Excellence (NICE) guidelines for this are summarised on the NICE website and an updated guideline will be available in 2020; a comprehensive toolkit is available at the British Sleep Society website, http://www.sleepsociety.org.uk. We also did not consider certain sleep disorders for which sets of guidelines already exist, such as narcolepsy (Billiard et al., 2006) and restless legs syndrome (Picchietti et al., 2015). Thus, the main scope of this document is to address insomnia, circadian rhythm disorders (CRDs) and the more common parasomnias which are likely to present to primary care physicians and psychiatrists.

The BAP is an association of psychiatrists, psychopharmacologists and preclinical scientists who are interested in the broad field of drugs and the brain. BAP is the largest national organisation of its kind worldwide, and publishes the Journal of Psychopharmacology. The association started publishing consensus statements more than two decades ago, and the first BAP guidelines on depression were considered a landmark publication when they appeared in 1993 (Montgomery et al., 1993). There are now guidelines for the treatment and management of most of the disorders encountered in psychiatry; all guidelines are available to download from the BAP website (http://www.bap.org.uk).

Method

This British Association for Psychopharmacology guideline replaces the original version published in 2010, (Wilson et al 2010) and contains updated information and recommendations. A consensus meeting was held in London in October 2017, attended by recognised experts and advocates in the field. They were asked to provide a review of the literature and identification of the standard of evidence in their area, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials (RCTs) where available, plus updates on current clinical practice. Each presentation was followed by discussion, aiming to reach consensus where the evidence and/or clinical experience was considered adequate, or otherwise to flag the area as a direction for future research. The previous consensus statement was then updated with the new evidence and references.

Categories of evidence for causal relationships, observational relationships and strength of recommendations are given in Table 1 and are taken from (Shekelle et al., 1999). The strength of recommendation reflects not only the quality of the evidence, but also the importance of the area under study. For example, it is possible to have methodologically sound (category I) evidence about an area of practice that is clinically irrelevant, or has such a small effect that it is of little practical importance and therefore attracts a lower strength of recommendation. However, more commonly, it has been necessary to extrapolate from the available evidence leading to weaker levels of recommendation (B, C or D) based upon category I evidence statements. The costs of the meeting were defrayed by BAP. All speakers completed conflict of interest statements that are held at the BAP office according to BAP policy.

Insomnia

Scope of the guidelines

Our intention is to provide an updated statement to guide clinicians who manage patients in primary or secondary medical care. There have been three sets of guidelines for the treatment of insomnia since the previous BAP consensus (Qaseem et al., 2016; Riemann et al., 2017; Sateia et al., 2017). The first set of guidelines concerns adults with insomnia and includes insomnia comorbid with other disorders such as depression; the second set addresses primary insomnia without comorbidity; the third set covers all adults with chronic insomnia disorder. These sets were discussed by the expert group and where appropriate some elements were incorporated in the present consensus.

Since the publication of the 2010 BAP guideline, there has been an important shift in thinking about the diagnosis and classification of insomnia. The historical perspective that insomnia could be either ‘primary’ or ‘secondary’, is no longer regarded as valid or evidence-based. Rather, the expanding literature has led the American Psychiatric Association (APA) (Diagnostic and Statistical Manual of Mental Disorders (DSM)-5) and the American Academy of Sleep Medicine (AASM) (International Classification of Sleep Disorders (ICSD)-3) to recommend that chronic insomnia disorder (APA) should be considered as a disorder in its own right.

This means that insomnia disorder should be diagnosed whenever insomnia diagnostic criteria are met, irrespective of any concurrent physical disorder or mental disorder; and, importantly, also irrespective of any other concurrent sleep disorder. It is anticipated that International Classification of Diseases 11th Revision (ICD-11) will reflect the same conclusions when it is presented at the World Health Assembly for adoption by member states in 2019.

Corresponding author:
Sue Wilson, Centre for Psychiatry, Division of Brain Sciences, Imperial College, Burlington Danes Building, Hammersmith Hospital campus, 160 Du Cane Road, London, W12 0NN, UK.
Email: sue.wilson@imperial.ac.uk
Strength of recommendation:
A — directly based on category I evidence.
B — directly based on category II evidence or extrapolated recommendation from category I evidence.
C — directly based on category III evidence or extrapolated recommendation from category I or II evidence.
D — directly based on category IV evidence or extrapolated recommendation from category I, II or III evidence.

The complex relationship between insomnia and psychiatric disorders has been the subject of much recent research. It is increasingly recognised that sleep plays a central role in the regulation of emotion and emotion processing (Palmer and Alfano, 2017; Tempesta et al., 2018). Therefore, it is not surprising to see a bidirectional relationship between insomnia and mental disorder. There is considerable evidence that pre-existing insomnia confers risk for the development of (or relapse into) depression. This makes it all the more important to consider the time-course of how insomnia and other psychiatric symptoms develop and resolve (Sánchez-Ortuño and Edinger, 2012).

Insomnia often starts with a specific problem, for example a stressful life event such as the loss of a job or change to a more demanding one; or through something that changes sleep patterns, such as the birth of a child or starting shift work. In some people this acute insomnia persists into a chronic state. Factors involved in the persistence of insomnia are not fully established, but include anxiety about sleep, maladaptive sleep habits and the possibility of an underlying vulnerability in sleep-regulating mechanisms. Persistence of the precipitating stressor can also contribute. Some cases of insomnia are precipitated by, or co-morbid with, other psychiatric disorders especially anxiety and depression, or by physical illness such as cancer or arthritis.

The nature of sleep changes with age. Older age is associated with poorer objectively-measured sleep with shorter sleep time, diminished sleep efficiency, and more arousals. These changes may be more marked in men than women according to a very large study of elderly people living at home in the USA (Sleep Heart Health Study: Unruh et al., 2008). In the same study, the association of subjective report of poor sleep with older age was stronger in women. The higher prevalence of chronic health conditions, including sleep apnoea, in older adults did not explain changes of sleep parameters with aging and age-sex differences in these relationships.

There is now greater consensus about how long insomnia should have been present before it merits intervention. Chronic insomnia is regarded as established after three months of persistent poor sleep. There is also general agreement that when insomnia causes significant personal distress or marked impairment then some form of treatment is appropriate. The cause of insomnia may be known or not, and knowledge of causation is not necessary for a diagnosis.

Epidemiology of insomnia

Studies of prevalence of insomnia in the general population indicate that one third of adults in Western countries experience difficulty with sleep initiation or maintenance at least once a week (LeBlanc et al., 2009; Leger and Poursain, 2005; Sateia et al., 2000), and 6–15% are thought to meet the criteria of insomnia in that they report sleep disturbance as well as significant daytime dysfunction (LeBlanc et al., 2009; Sivertsen et al., 2009). One-year incidence rates have been reported to be 30.7% for insomnia symptoms and 7.4% for insomnia syndrome. These rates decreased to 28.8% and 3.9% for those without a prior lifetime episode of insomnia (LeBlanc et al., 2009). There is much evidence that insomnia can be a long-term disorder. In one large UK study, about three-quarters of patients reported symptoms lasting at least a year (Morphy et al., 2007) and, in a population-based three-year longitudinal study, 46% of subjects who had insomnia at baseline still had it at the three-year time point. The course of insomnia was more likely to be persistent in those with more severe insomnia at baseline and in women and older adults (Morin et al., 2009). Two studies have described an increase of insomnia over time: in the UK, insomnia diagnosis increased from 3.1% to 5.8% (National Psychiatric Morbidity Surveys 1993–2007; Calem et al., 2012); and in Norway, insomnia diagnosis increased from 11.9% to 15.5% between two surveys in 2000–2010 (Pallesen et al., 2014).
There is a higher incidence of insomnia in women, and the incidence increases in men and women as they get older (see below – special populations). The symptom prevalence changes with age, so that people aged over 65 years show more sleep maintenance problems but a decrease in reported daytime problems compared with younger age groups, with little change in the prevalence of sleep onset insomnia.

**Diagnosis of insomnia**

Diagnostic criteria from the APA, AASM and World Health Organization (WHO) are summarised in Table 2. They agree that insomnia is a complaint of unsatisfactory sleep, either in terms of sleep onset, sleep maintenance or early waking. In DSM-5 and ICSD-3 this complaint must be present three or more nights per week, for at least three months, and be associated with impairment to day-time functioning or well-being. In this sense insomnia can be considered a ‘24-hour’ disorder, because a complaint of unsatisfactory sleep without reported functional sequelae would not meet clinical diagnostic criteria.

Like other disorders and conditions classified within DSM-5, insomnia is largely a subjectively determined disorder. Polysomnographic (PSG) and actigraphic studies do indicate that people with insomnia take longer to fall asleep and have sleep that is more fragmented than healthy good sleepers. However, these parameters do not reflect the level of sleep disturbance reported by people with insomnia; and they do not sample daytime experience. Moreover, PSG and actigraphy are not indicated for use in insomnia – except if other sleep disorders are suspected (Sateia et al., 2017) – and, in any case, are seldom available in routine care.

Like depression, anxiety or pain, there is no objective test for insomnia, and in practice it is evaluated clinically. Diagnosis, therefore, is through appraisal against diagnostic criteria, clinical observations and the use of validated rating scales.

There are a number of ways in which sleep can be assessed. The simplest is by asking the patient about their sleep. Are they having difficulty getting to sleep and/or staying asleep? Is this occurring most nights? Is this persistent and affecting how they feel during the day?

An extension of this interview enquiry is to administer a clinical rating scale. The Sleep Condition Indicator (SCI) is one such scale being based on contemporary diagnostic criteria and has been validated in over 200,000 adults. It also has a short-form screening version comprising only two items (Espie et al., 2014, 2018b; Luik et al., 2019; see Appendix 1).

A further step is to provide the patient with a sleep diary. This allows the assessment of sleep difficulties over time, and gauges the potential contribution of poor sleep and lifestyle habits to daytime impairment. Some patients appreciate completing a diary to capture the nature of their sleep problems, including the unpredictability of their sleep from night to night. The SCI and the diary may also be useful to assess treatment-related change.

Finally, it is important to determine if another sleep disorder (see preliminary questions below), or a physical (such as pain, heart or metabolic disease), neurological (such as Parkinson’s disease or cerebrovascular disease) or psychiatric (such as depressive illness, anxiety disorder or substance use disorder) disorder is present alongside the insomnia. The insomnia problem should be actively treated, but consideration of the interplay between conditions is good clinical practice. A diagram illustrating diagnosis is given in Figure 1.
Comorbidity
There is a generally high incidence of sleep disorders in psychiatric conditions. The most widely reported are shown below:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sleep Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major depressive disorder</td>
<td>Up to 70% insomnia</td>
</tr>
<tr>
<td>Post-traumatic stress disorder (PTSD)</td>
<td>Up to 15% hypersomnia</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Insomnia</td>
</tr>
<tr>
<td></td>
<td>Nightmares</td>
</tr>
<tr>
<td></td>
<td>Non-REM parasomnia CRD</td>
</tr>
</tbody>
</table>

Insomnia is now recognised as reliably associated with mental health disorders including risk of depression and suicide (Baglioni and Riemann, 2012; Pigeon et al., 2017), cardiovascular disease (Khan and Aouad, 2017) and type 2 diabetes (Cappuccio et al., 2010; Vgontzas et al., 2009). Increased fatigue, impaired work productivity, reduced quality of life, and relationship dissatisfaction are also common in those with insomnia (Espie et al., 2012; Kyle et al., 2010; Roth and Ancoli-Israel, 1999). Indeed, such impaired functioning is an important driver for help-seeking behaviour (Morin et al., 2006).

There is at least a two-fold increased risk of subsequent depression and anxiety disorder in patients with pre-existing insomnia (Baglioni and Riemann, 2012). Insomnia has been associated with: (a) an increased risk of developing subsequent depression; (b) an increased duration of established depression; and (c) relapse following treatment for depression (Riemann, 2009). Poor sleep quality also seems to correlate with high negative and low positive emotions, both in clinical and subclinical samples. Good sleep seems to be associated with high positive emotions, though not necessarily with low negative emotions (Baglioni et al., 2010).

The strong relationship between insomnia and emotional vulnerability has been established for 30 years. The National Institute of Mental Health Epidemiologic Catchment Area interviewed 7954 adults on two occasions a year apart, and highlighted the strong association between sleep disturbance and subsequent depression. It was found that 14% of those with insomnia at the first interview had developed a new major depressive episode one year later (Ford and Kamerow, 1989). This increased risk of developing depression has been confirmed in numerous investigations: in a survey of 1200 young adults in Michigan, the odds ratio of new depression was four times greater in those subjects who had insomnia three years earlier (Breslau et al., 1996) and of new anxiety disorder the risk was
two-fold greater. In a questionnaire survey of adults in the UK, there was a three-fold increased risk of new depression and a two-fold risk of new anxiety disorder if subjects had reported one sleep problem occurring ‘on most nights’ a year earlier (Morphy et al., 2007). In a much longer study in Norway, with two surveys 10 years apart (Neckelmann et al., 2007), the risk of having an anxiety disorder diagnosis at the second time point increased by about one and a half times if insomnia had been present at the first time point, and about five times if insomnia was present at both time points. Doctors in a prospective study who had complained of insomnia whilst studying at medical school in the 1950s and 1960s were twice as likely to have developed depression at follow-up in the 1990s (Chang et al., 1997).

Insomnia is associated with activation of the hypothalamic-pituitary-adrenal (HPA) axis, with increased adrenocorticotropic hormone (ACTH) and cortisol in most studies (Varkevisser et al., 2005; Vgontzas et al., 1998; Vgontzas et al., 2001). When the complaint of insomnia is accompanied by short duration of sleep measured objectively, there is a 3–5-fold increase in overall risk of hypertension which is comparable to that seen with other common sleep disorders, such as sleep disordered breathing (Vgontzas et al., 2009). In France, Japan and the USA, insomnia patients scored significantly lower on all eight domains of the SF-36 quality of life questionnaire, compared with good sleepers (Leger, 2012).

People with a diagnosis of insomnia also have subjective complaints of poor daytime function. When compared with matched controls, they show increased subjective sleepiness but decreased objective sleepiness, due to the fact that they are usually over-aroused, but feel subjectively tired. Objectively, they show poorer performance on psychomotor tasks, particularly those requiring the switching of attention (e.g. frontal/executive tasks) (Edinger et al., 2008); objectively measured time awake after sleep onset (WASO) was the best predictor of impaired daytime performance. Likewise, Altena et al. (Altena et al., 2008) reported that people with insomnia perform more poorly on complex cognitive tasks, an effect which normalises following cognitive behavioural therapy (CBT) intervention. A meta-analysis of 24 studies (Fortier-Brochu et al., 2012), comparing the daytime cognitive performance of people with insomnia and good sleeper controls found that those with insomnia exhibited performance impairments of small to moderate magnitude in working memory, episodic memory and some aspects of executive functioning. However no significant group differences were observed for tasks assessing general cognitive function, perceptual and psychomotor processes, procedural learning, verbal functions, different dimensions of attention (alertness, complex reaction time, speed of information processing, selective attention, sustained attention/vigilance) and some aspects of executive functioning (verbal fluency, cognitive flexibility).

The economic burden of insomnia is high, with overall costs thought to exceed US$100 billion per year in the USA (Wickwire et al., 2016). In Europe, the economic costs of insufficient sleep, including disruption from insomnia and other sleep difficulties were modelled across five countries; in the UK costs were estimated at 1.86% of Gross Domestic Product or US$50 billion to the economy (Hafner et al., 2017). Costs are both direct (prescription costs, appointments and inpatient care) and indirect (lost workplace productivity/presenteeism, absenteeism, and increased risk of traffic and workplace accidents) (Daley et al., 2009; Leger et al., 2014). Increased insomnia severity has also been shown to be associated with increased healthcare utilisation (Wickwire et al., 2016) and people with insomnia have higher healthcare costs than controls (Wickwire et al., 2019). The majority of studies indicate that the cost of treating insomnia is less than the cost of not treating insomnia, and that treatment costs appear to be recouped within 6–12 months (Morgan et al., 2004; Wickwire et al., 2016).

Recommendations

It is important to treat insomnia because the condition causes decreased quality of life, is associated with impaired functioning in many areas, and leads to increased risk of depression, anxiety and possibly diabetes and cardiovascular disorders (A).

Goal of treatment:

- To lessen suffering.
- Improve daytime function.

Type of treatment:

- Cognitive-behavioural therapy for insomnia (CBTi) should be offered as first line treatment.
- In case of treatment failure, unavailability of CBTi, or inability to engage with CBTi, pharmacological treatment with an evidence base should be offered (see Figure 2).
Psychological treatment of insomnia

**What is known about psychological treatment of insomnia:**
- CBTi is an effective treatment for insomnia when delivered individually or in small group format (Ia).
- CBTi is an effective treatment for insomnia when delivered digitally as a Web/mobile intervention (Ia).
- CBTi is as effective as prescription medications for short-term treatment of chronic insomnia. Moreover, there are indications that the beneficial effects of CBT may last well beyond the termination of active treatment (Ia).
- Improvements in sleep following CBTi for chronic insomnia mediate improvements in mental health symptoms, wellbeing and quality of life (Ia).

**What is not known:**
- What are the predictors of failure to respond to CBTi?
- Does hypnotic medication enhance the effects of CBTi and, if it does, under what circumstances?

**Underpinning principles – CBT.** Psychological treatment of insomnia should be considered appropriate for a number of reasons.

First, insomnia has across diagnostic and classification systems been long regarded as a ‘psychophysiological’ disorder in which mental and behavioural factors play crucial roles as predisposing, precipitating and perpetuating factors (Espie, 2002; Espie et al., 2006; Kalmbach et al., 2018; Riemann et al., 2010; Spielman et al., 1987). Core features of insomnia are heightened arousal and learned sleep-preventing associations. Arousal can reflect a general cognitive hypervigilance and many patients describe ‘racing thoughts’ as a problem when they are trying to sleep. A cycle develops in which the more one strives to sleep, the more agitated one becomes, and the less able one is to fall asleep. All of these sleep-related behaviours and attitudes contrast with those of the ‘good sleeper’ who seems to sleep without much thought or planned behaviour.

Second, CBTi directly addresses these cognitive and behavioural factors, particularly those that maintain insomnia. CBTi employs a package of interventions designed to encourage ‘poor sleepers’ to think and behave like ‘good sleepers’. The therapy is manualised and health professionals can be trained to administer it either individually or in a group setting. Therapies are multi-modal, embodying techniques such as sleep restriction and stimulus control as well as cognitive restructuring. CBT then is a treatment modality, as is pharmacotherapy. The latter comprises a range of licensed medications, and the former a range of proven psychotherapeutic methods.

Third, and most importantly, there is a substantial evidence base for the safety, efficacy and clinical effectiveness of CBTi. Systematic reviews and meta-analyses have consistently found that CBTi reduces sleep latency and the duration and frequency of night-time wakings, as well as increasing sleep efficiency with moderate to large effect sizes. CBT also increases total sleep time, and the benefits of CBTi are durable at medium to long-term follow up.

Importantly, side-effects with CBTi are relatively minimal, with some patients reporting mild daytime sleepiness in the early stages of sleep restriction and stimulus control. However, there is considerable evidence of generalised benefit to mood, wellbeing, and to social and occupational functioning in controlled trials (Espie et al., 2018a; Van Houdenhover, 2011). Recent insomnia CBT studies have demonstrated a causal relationship between improvements in sleep and improvements in mental health symptoms, wellbeing and quality of life (Espie et al., 2018a, b; Freeman et al., 2017)

CBTi is therefore lastingly effective, and is the recommended treatment of first choice for chronic insomnia in guideline documents (e.g. American College of Physicians: Qaseem et al., 2016; European Insomnia Guidelines, Riemann et al., 2017).

A longstanding problem for CBTi is not its effectiveness but its availability. At the time of writing of the 2010 BAP guideline, reference was made to this ongoing challenge and how it hindered real world implementation. CBT is traditionally offered face-to-face and so has been restricted by the number of available therapists to provide treatment. The advent of digital CBT (dCBT; Web and mobile delivery) has changed this landscape.

There are now four published meta-analyses of dCBT which indicate comparable effectiveness to in-person CBTi and demonstrate the emerging opportunity for patients to access this form of CBT treatment (Cheng and Dizon, 2012; Seyffert et al., 2016; van Straten et al., 2018; Zachariae et al., 2016). Two dCBT interventions in particular have a considerable evidence base. There are seven published RCTs of the SHUT-i product (with a total sample size n=2100) and eight published RCTs of the Sleepio product (total n=6900). The available evidence base is not just for CBT (in general), but also for discrete dCBT ‘products’; a situation that more closely aligns with the pharmaceutical literature where specific drugs can be seen as discrete pharmacotherapy products that can be offered as part of a formulary-driven pharmacopeia.

**Recommendations**

CBT-based treatment packages for chronic insomnia including sleep restriction and stimulus control are effective and therefore should be offered to patients as a first-line treatment (A).

Both face to face CBTi and dCBT are efficacious (A).

dCBTi has the potential to offer patients and clinicians a choice amongst evidence-based alternatives (CBT or drugs) in routine clinical care (A).

**Drug treatments for insomnia**

What is known about drug treatments for short-term treatment of insomnia:
- Gamma-aminobutyric acid (GABA)-positive allosteric modulators (PAMs) are efficacious for insomnia (Ia).
- Safety concerns (adverse events and carry-over effects) are fewer and less serious in hypnotics with shorter half-lives (Ib).
- Prolonged release melatonin improves sleep onset latency and quality in patients over 55 years (Ib).
- Suvorexant is efficacious in insomnia (Ia).
- Doxepin in very low doses (3 mg and 6 mg) is efficacious in insomnia (Ia).

What is not known:
- Does improvement in insomnia last after treatment is stopped?
- Does treatment reduce the risk of subsequent depression?
- Who responds and who does not?
**Underpinning principles – pharmacology.** Most drugs which affect the brain do so by affecting neurotransmitter function in the brain, which they can do by:

- simulating the action of a brain neurotransmitter on the receptor (agonists, partial agonists)
- blocking neurotransmitter action on postsynaptic receptors (antagonists)
- changing receptor sensitivity (allosteric modulators)
- increasing the amount of neurotransmitter present in the synapse, either by increasing the release of it into the synaptic cleft, blocking its transportation out of the cleft, or preventing the action of enzymes which break it down.

Arousal is maintained by parallel neurotransmitter systems with cell bodies located in brainstem or midbrain centres, with projections to the thalamus and forebrain. These activating neurotransmitters are noradrenaline, serotonin (5-HT), acetylcholine, dopamine, histamine and the orexin system with cell bodies in the hypothalamus, which together promote wakefulness through regulating arousal pathways (and inhibiting sedating ones). For all of these arousing neurotransmitters, waking can be promoted by increasing their function, and sleep or sedation by decreasing their function in the brain.

The promotion of sleep is regulated by a number of other neurotransmitters; primary amongst these is GABA, the main inhibitory neurotransmitter in the brain. The majority of brain cells are inhibited by GABA so increasing its function reduces arousal and produces sleep, and eventually anaesthesia. There are many subsets of GABA neurones distributed throughout the brain but a particular cluster in the hypothalamus (ventrolateral preoptic nucleus) can be considered to be the sleep ‘switch’ (Saper et al., 2005). These neurones ‘switch off’ brain arousal systems at the level of the cell bodies and therefore promote sleep. GABA receptors in the cortex can also promote sedation and sleep by inhibiting the target neurones of the arousal system. Benzodiazepines, so-called ‘Z drugs’ and barbiturates all enhance inhibiting the target neurones of the arousal system. Benzodiazepines, so-called ‘Z drugs’ and barbiturates all enhance receptors in the cortex can also promote sedation and sleep by regulating the action of enzymes which break it down.

Histamine neurons form part of the neurotransmitter network promoting arousal. Histamine levels are high in daytime and low during sleep. Drugs which reduce histamine function (H1 receptors or histamine antagonists) reduce arousal. Antihistamine medications which cross the blood-brain barrier, such as promethazine and diphenhydramine, are widely used ‘over-the-counter’ and prescribed to promote sleep. Unfortunately, they are not selective for histamine, and their actions at other brain receptors (particularly antagonism at cholinergic, noradrenergic and (promethazine) dopaminergic receptors contribute to an adverse effect profile. The most selective available medication is very low dose doxepin, which, at doses from 1–6 mg, has little or no effect at brain receptors other than H1 receptor antagonism. This drug is approved in the USA for insomnia, but is not available in Europe. Esmirtazapine, the S-enantiomer of mirtazapine is also selective for H1 receptors, and is undergoing evaluation (Ivgy-May et al., 2015; Ruwe et al., 2016).

Orexin is a neurotransmitter intimately involved in sleep and waking. When the orexin receptors 1 and 2 (OR1 and OR2) in the hypothalamus are activated they promote waking, and antagonists for these have been found to promote sleep. Several receptor antagonists have been developed and one, suvorexant, is licensed in the USA for insomnia (Herring et al., 2016). These drugs are not yet available in Europe but several agents are being evaluated in clinical trials.

Melatonin is produced in the pineal gland and has an important role in regulating circadian rhythms (Cajochen et al., 2003; Dijk and von Schantz, 2005). The circadian ‘pacemaker’ is the suprachiasmatic nucleus (SCN) of the hypothalamus and when active it inhibits melatonin secretion in the pineal gland. Once melatonin appears in the plasma it enters the brain and binds to melatonin receptors in the hypothalamus. Melatonin has both phase-shifting effects, so changing the timing of the biological clock, and direct sleep-facilitating effects. Administering exogenous melatonin or analogues such as ramelteon (licensed in the USA) can promote sleep onset. A slow-release formulation of melatonin has been licensed on the basis of improved sleep continuity and daytime well-being in people aged over 55 years with insomnia. Melatonin production is reported to decline with age and to be lower in middle-aged and elderly patients with insomnia than in good sleepers (Attenburrow et al., 1996; Dwolig et al., 2008; Haimov, 2001; Leger et al., 2004). Beta-adrenergic receptor blockers and non-steroidal anti-inflammatory drugs inhibit melatonin secretion.

**Underpinning principles – pharmacokinetics.** The principles of the ideal drug for insomnia have been discussed for decades and are outlined in Figure 3. All licensed drugs for insomnia improve one or more aspects of subjective sleep, and some also improve daytime functioning (see below – but note that many drugs have not been evaluated on this parameter).

Kinetic aspects are important both in terms of how quickly the drug enters the brain and how long its effects last (for comparison of drugs see Tables 3 and 4 in Wilson et al., 2010). The faster the drug enters the brain, the sooner sleep is induced. Some agents used for insomnia have not been active in this aspect of sleep because of poor kinetic properties: for example, temazepam tablets have a poorer bioavailability and slower absorption (and thus a longer presence in the body) than the previous gel formulations. Drugs that enter the brain very quickly, though effective, may need to be taken in the bedroom or even in bed to prevent people falling asleep before they are in bed (see Zentiva Pharma UK Limited, 2002; zolpidem Summary of Product Characteristics (SPC)).
The ease of waking and the propensity to daytime carry-over (‘hangover’) effects are determined by the duration of action – with GABA-PAMs this is typically defined by the elimination half-life of the drugs (see Tables 3 and 4 in Wilson et al., 2010) and the dose taken. Drugs with half-lives of more than six hours tend to leave sufficient residual drug in the brain to cause hangover effects in the morning. This was particularly the case with the first benzodiazepine drugs for insomnia such as nitrazepam, which was associated with daytime sedation and falls (Trewin et al., 1992). The rationale for developing zopiclone, zolpidem and zaleplon was to make shorter half-life drugs with minimal carry-over effects (Nutt, 2005b). This was largely achieved, although some hangover effects are seen with zopiclone and eszopiclone (Boyle et al., 2012; Staner et al., 2005).

A very short half-life limits a drug’s duration of action on sleep, and zolpidem is less effective at maintaining sleep throughout the night than drugs with a longer half-life. A controlled release formulation of zolpidem (currently only available in the USA) prolongs its nocturnal actions and enhances sleep continuity, though only by 10s of minutes (Greenblatt et al., 2006). Individual factors seem important and some people are more susceptible to carry-over effect than others, probably due to individual differences either in the rate of drug clearance, which can vary by as much a two-fold between subjects, or sensitivity to drug actions. In particular, women tend to have higher blood concentrations of zolpidem, and greater impairment of driving ability, the following morning than do men (Farkas et al., 2013). The US Food and Drugs Administration responded to this finding by requiring manufacturers to recommend gender-specific labelling with dosing for women being half that of men.

**Tolerance, dependence and withdrawal.** Dose escalation above recommended doses in patients with insomnia alone appears uncommon, and tolerance to the effects of GABA-PAM drugs for insomnia is not a frequently encountered problem in clinical experience. Many patients use the same dose for months or years and still feel it works. However, a temporary worsening of sleep, usually with increased sleep onset latency, is reported during the withdrawal period for most GABAergic agents (Hajak et al., 2009; Soldatos et al., 1999; Voshaar et al., 2004). Although there have been no head-to-head studies of this question, there is some lower level evidence in humans that subtype-selective drugs such as eszopiclone produce less tolerance and rebound (Krystal et al., 2003; Nutt and Stahl, 2010).

Animal and human research demonstrates that brain receptor function changes in response to chronic treatment with benzodiazepine receptor agonists, and this takes time to return to pre-medication levels after cessation of medication. There is evidence from animal studies that chronic administration of benzodiazepines produces adaptive changes in the receptor which attenuate the effects of the endogenous neurotransmitter GABA, and so produce symptoms on withdrawal (Bateson, 2002). It may be possible to develop drugs with a lower propensity to such effects: through targeting specific subtypes of the benzodiazepine receptor by changing the chemical structure to produce a different interaction at the pharmacophore; or by making partial agonists (Doble et al., 2004).

Considerations of dependence on GABA-PAMs are contingent on what happens when treatment is stopped. A psychological dependence is seen in many patients and some are reluctant to stop treatment. If they do stop, there can be relapse, where the patient’s original symptoms return; or rebound of symptoms, where for one...
or two nights there is a worsening of sleep disturbance, with longer sleep onset latency and increased waking during sleep; this is commonly reported by patients and has been documented in some research studies (Hajak et al., 2009; Soldatos et al., 1999). More rarely, there is a longer withdrawal syndrome. All of these can be ameliorated by resuming medication. The withdrawal syndrome is characterised by the emergence of symptoms not previously reported, such as agitation, headache, dizziness, dysphoria, irritability, fatigue, depersonalization, hypersensitivity to noise and visual stimuli. Physical symptoms which have been described include nausea, vomiting, muscle cramps, sweating, weakness, muscle pain or twitching and ataxia. This syndrome usually resolves within a few weeks, but persists in some patients, and this persistence may be related to personality traits and cognitive factors (Murphy and Tyrer, 1991).

**Pharmacological treatment of insomnia.** All licensed drugs licensed for insomnia are efficacious (I). As explained above, some may improve sleep earlier in the night, as they enter the brain more quickly, and thus reduce sleep onset latency. Duration of action depends to a great extent on half-life and for instance in a patient with predominantly sleep-onset insomnia, a shorter acting drug such as zolpidem or melatonin might be appropriate, and for those with awakenings throughout the night a slightly longer acting drug such as zopiclone may be preferable.

Most of the drugs approved for insomnia enhance GABA function in the brain. As well as promoting sleep these drugs are anxiolytic, anticonvulsant and myorelaxant, and can cause ataxia and memory problems when taken other than just before a period in bed. If their effect in the brain persist after waking in the morning they are sometimes described as ‘hangover effects’ therefore differences in the pharmacokinetics of individual benzodiazepines (or ‘Z drugs’) are particularly important. Melatonin does not give rise to motor or memory effects; however the synthetic melatonin agonist ramelteon gives rise to sleepiness which can persist for 12–14 h (Cohen et al., 2010). Recent clinical trials have measured daytime outcomes after drugs for insomnia, and beneficial effects have been reported for melatonin in those over 55 years, and for zolpidem, zopiclone, eszopiclone and lorazepam. These measures have not been used in studies of other drugs, so their effects on daytime function are not documented.

In systematic reviews of GABA-PAMs, adverse events/side effects are less common and less severe for the Z-drugs zolpidem and eszopiclone (Buscemi et al., 2007). Controlled studies measuring cognitive and psychomotor function (such as digit-symbol substitution test, and memory) in insomnia patients have only shown next-day deleterious effects consistently after use of flurazepam (very long-acting) or very high doses of other benzodiazepines (Buscemi et al., 2005). Evidence for hypnotic effects on next day driving in insomnia patients is limited, however epidemiological studies show that road accidents are increased in people taking benzodiazepines or zopiclone (Barbone et al., 1998; Neutel, 1995). Studies in healthy volunteers show that residual effects of drugs for insomnia increase with their half-life duration (Verster et al., 2006). Effects of insomnia itself on driving have not been studied extensively, though sleep deprivation does impair driving performance (Connor et al., 2002). In a controlled study of patients with insomnia in a driving simulator, there was next-day impairment after zopiclone and lorazepam but not zolpidem, when compared with placebo (Staner et al., 2005).

Very low doses of doxepin, (1, 2 or 6 mg when doxepin acts only as a histamine antagonist) improve sleep in adult (18–65 years) and elderly (65 years and older) insomnia patients (Yeong et al., 2015). Doxepin has a preferential effect on reducing awakenings in the latter half of the night (Krystal et al., 2010) and does not appear to give rise to residual daytime effects (Krystal et al., 2011). Suvorexant, an antagonist at OR1 and OR2 receptors, improves sleep in adult and elderly insomnia patients. It increases subjective total sleep time and decreases subjective wake time in the middle and end of the night and subjective time to sleep onset; a few healthy volunteers had impairment of driving ability nine hours after higher doses of suvorexant (Vermeeren et al., 2015). Neither of these drugs is currently available in Europe.

**Recommendations**

Factors which clinicians need to take into account when prescribing are efficacy, safety, and duration of action (A).

Other factors are previous efficacy of the drug or adverse effects, history of substance abuse or dependence (D).

**Long-term use of sleeping medications**

- Insomnia is often long-lasting and is in practice often treated with hypnotics for long periods in clinical practice (I).
- Studies suggest that dependence (tolerance/withdrawal) is not inevitable with hypnotic therapy up to one year with eszopiclone, zolpidem, ramelteon (II).
- Intermittent dosing may reduce the risk of tolerance and dependence (II).

**What is not known:**

- How can we predict the needed treatment duration?
- How and when should treatment be discontinued?
- Should dosing for longer periods be nightly or intermittent?
- How do we detect the abuse prone individual in the clinic?
- Does hypnotic therapy affect the course of insomnia or associated conditions?

The question of long-term hypnotic treatment is one of the more controversial areas in psychopharmacology. It has long been stated that sleeping medication should not be used long-term for the treatment of insomnia. This was the consensus view of the panel of a 1983 National Institute of Health (NIH; 1983) Consensus Conference on the medication treatment of insomnia, which became a guideline for clinical practice in the USA, and later the UK Committee on Safety of Medicines and the Royal College of Psychiatrists both recommended only short-term use. While it was appreciated that benzodiazepine hypnotic agents had a favourable risk-benefit ratio and were first-line agents for insomnia management, all of these reports expressed concerns about the risks of physical dependence and recommended their use should be limited to periods of 2–3 weeks. Despite the recommendation for treatment with hypnotic drugs being only 2–4 weeks, many millions of patients worldwide remain on long-term treatment (Ohayon et al., 1999; Maust et al., 2019).

The reasons for longer term use are complicated and difficult to research but are probably similar to those which affect...
understanding of longer term benzodiazepine treatment in patients with anxiety disorders. We do not know the proportions of longer term users that have continuing insomnia requiring daily drug treatment, or who do not need the drug at all, or who are afraid to try discontinuing because of fear or experience of rebound insomnia. In one study where people were successful in discontinuing benzodiazepine hypnotics, a follow-up after two years revealed approximately 40% had resumed regular use (Belanger et al., 2005; Morin et al., 2005a), which suggests some people have enduring problems with sleep which benefit from treatment. Insomnia may have some similarities with depression, in that both represent long-term disorders in which maintenance treatment may be needed in many patients (Jindal et al., 2004). A related issue is whether early intervention at the onset of insomnia might reduce the likelihood of it persisting.

Placebo-controlled trials of treatment for durations longer than three weeks can more definitely assess safety and efficacy, and determine whether dependence phenomena occur, have been undertaken. Trials of nightly dosing for up to 12 months duration suggest that tolerance and withdrawal do not generally occur with some hypnotics: zolpidem (one study of 12 months and one of eight months duration); ramelteon (a six-month study with outcome assessed with polysomnography but not self report); and temazepam (a two-month study) (Ancoli-Israel et al., 2010; Bastien et al., 2003; Krystal et al., 2003; Mayer et al., 2009; Morin et al., 1999; Roehrs 2012; Walsh et al., 2007). Others agents have not been studied for longer durations. The available evidence does not suggest there is an unfavourable risk/benefit transition at 3–4 weeks for any agent.

Open-label studies of nightly dosing for periods up to one year with the agents studied (zolpidem, eszopiclone, and ramelteon) suggest that discontinuation symptoms are generally mild and infrequent (Ancoli-Israel et al., 2005; Randall, 2012; Richardson et al., 2009). Intermittent, non-nightly, dosing is also an important consideration with respect to long-term hypnotic treatment. Many individuals do not have nightly insomnia and treatment only when needed can decrease the risks and costs of therapy and reduce psychological dependence/treatment withdrawal anxiety. There is evidence from a placebo-controlled trial for sustained efficacy and safety for six months of ‘as needed’ treatment (subjects being required to take at least three doses per week) with controlled release zolpidem 12.5 mg (Krystal et al., 2008).

In conclusion, insomnia is often long-lasting and often treated with hypnotics for long periods in clinical practice. Controlled trials of longer-term use are being undertaken and these suggest dependence (tolerance/withdrawal) is not inevitable with hypnotic therapy up to one year, and is not characteristic of the several agents studied. The longer-term safety and efficacy of many other commonly used hypnotics remains uncertain.

A number of critical issues remain unresolved. We currently lack the means to determine who should receive longer-term treatment and to predict the required treatment duration. Lacking the means to determine the optimal duration of therapy, a rational approach is to carry out periodic trials of tapering and discontinuing medication to determine if continued therapy is indicated (Krystal, 2009). As such, the duration of treatment is decided by a series of risk/benefit decisions based on trial discontinuations. This approach provides an ‘exit strategy’ and addresses concerns that once started hypnotic therapy could be unending. Concomitant CBT during tapered discontinuation is helpful (Morin et al., 2004; Parr et al., 2009; Belleville et al., 2007). Another unresolved issue is whether to implement nightly or intermittent dosing of hypnotics for a given patient. It is clear that the medication works on the nights it is taken but poor sleep occurs when it is not. In many instances this is a practical decision based on whether the patient can predict when they go to bed whether they will have sleep difficulty. In addition, some have argued that intermittent dosing may reinforce psychological dependence on the drug.

**Recommendations**

Use as clinically indicated (A).

In general, hypnotic discontinuation should be based on slowly tapering off medication (A).

CBT during taper improves outcome (A).

**Using drugs for depression to treat insomnia**

What is known about the use of drugs for depression to treat insomnia:

- There is limited evidence for efficacy of trimipramine, trazodone and paroxetine in insomnia (Ib).
- Older drugs for depression may affect a wide range of brain receptors and have longer lasting carry-over effects than traditional drugs for insomnia. They are associated with increased risks of road accidents especially early in treatment in depression (Ib).

What is not known:

- Duration of effect (particularly as they are often prescribed for long periods).
- How their effects compare with approved medications for insomnia.

Tricyclic antidepressants have long been used for insomnia, with little evidence of efficacy (see Everitt et al., 2018), whereas the serotonin reuptake inhibitors (SRIs) as a class generally disrupt sleep early in the course of treatment (Mayers and Baldwin, 2005). The alerting effect of SRIs can sometimes be offset by co-administration of sedating drugs for depression such as trazodone, probably because they block 5-HT2 receptors that are being overstimulated by an increase in 5-HT (Kaynak et al., 2004); alpha-1 adrenergic antagonism may also contribute. Other 5-HT2 antagonist drugs for depression such as nefazodone (now discontinued) (Hicks et al., 2002) and mirtazapine (Winokur et al., 2003) have been shown to reduce insomnia in depression, especially early in treatment.

Low doses (sub-therapeutic for depression) of sedating tricyclics, particularly amitriptyline, have been used for decades to treat insomnia. This is particularly common practice in primary care in the UK, where amitriptyline 10 or 25 mg is also used for long periods in many patients with chronic illness, particularly those with pain syndromes. At this dose, amitriptyline is probably acting mostly as a histamine H1 receptor antagonist although a degree of 5-HT2 and cholinergic muscarinic antagonism may also contribute. There are no controlled studies of hypnotic efficacy of low-dose amitriptyline in insomnia, and tricyclics are more likely to be lethal than licensed hypnotics in overdose (Nutt, 2005a). Controlled trials demonstrate an effect of doxepin...
in insomnia at sub-antidepressant dose (25 mg) (Hajak et al., 2001) for four weeks, with rebound insomnia.

Trazodone is an agonist at 5-HT1A receptors, an antagonist at 5-HT2 and α1 adrenergic receptors and a weak 5-HT reuptake inhibitor: it is the second most prescribed medication for insomnia in the USA. It has a perceived absence of risk and is cheap, but 25–30% patients experience difficulty tolerating trazodone and dropout rates tend to be higher than for benzodiazepine hypnotics or Z-drugs. Although there have been 18 trazodone studies measuring sleep outcomes, only two were in primary insomnia, and only one was a controlled study (Walsh et al., 1998). This study used 50 mg trazodone vs placebo, and found a significant effect on sleep maintenance parameters at week 1 but not week 2, and a high incidence of daytime somnolence. Trimipramine is a drug for depression which blocks α1 adrenergic, histamine H1, dopamine D2, 5-HT2 and cholinergic receptors (Gross et al., 1991; Richelson, 1994). There is one controlled trial (Rieman et al., 2002) in insomnia at doses of 50–200 mg for four weeks which found a significant improvement in sleep efficiency as measured by polysomnography, paralleled by subjective improvements. Side effects were described as marginal. Paroxetine, an SRI, was studied in patients with insomnia aged over 55 years, at a median dose of 20 mg for six weeks (Reynolds, III et al., 2006), there being a 50% response rate (placebo 38%) with subjective sleep quality and daytime well-being improved. This seeming paradoxical action of paroxetine to improve sleep is probably related to its high incidence of daytime somnolence. Trisomnism is an SRI, an α1 adrenergic, histamine H1, dopamine D2, 5-HT2 and cholinergic receptor: it is the second most prescribed medication for insomnia (11%) (Birtisch et al., 2014).

PSG sleep studies in healthy participants have shown changes in sleep architecture. These include increases in slow wave sleep and decreases in rapid eye movement (REM) sleep with ziprasidone and olanzapine (Cohrs et al., 2004; Cohrs et al., 2005; Sharpley et al., 2000). Some positive changes in measures of sleep maintenance have been shown with clozapine, quetiapine, olanzapine and risperidone (Gimenez et al., 2007; Lindberg et al., 2002; Sharpley et al., 2000). Subjective sleep was improved by risperidone, olanzapine and quetiapine.

In models of transient insomnia, such as acoustic stress and phase advance in healthy volunteers, quetiapine, ziprasidone and lurasidone have shown improvements in sleep initiation and maintenance (Cohrs et al., 2004, 2005; Karsten et al., 2017; Krystal and Zammit, 2016).

In patients with schizophrenia (see Monti et al., 2017) clozapine increased total sleep time (Kluge et al., 2014); olanzapine increased slow-wave sleep and improved sleep–continuity measures (Gao et al., 2013; Kluge et al., 2014; Monti et al., 2017; Muller et al., 2004; Salin–Pascual et al., 1999, 2004). Quetiapine administration has generated mixed results in patients with schizophrenia, with Loebel et al. (2014) finding increases in daytime sleepiness after six weeks quetiapine extended release (XR) 600 mg compared with placebo, whereas Keshavan et al. (2007) found reduced sleep continuity compared with drug naive patients.

In bipolar patients (see Monti et al., 2016) six months add-on clozapine treatment increased total sleep time compared with baseline (Armitage et al., 2004). Risperidone and olanzapine both improved sleep continuity when added to an SRI in depression (Sharpley et al., 2003; 2005; Lazowski et al., 2014). Furthermore, Moreno et al. (2007) found that olanzapine improved sleep continuity in patients with bipolar disorder during a manic episode. Using actigraphy, Todd et al. (2006) and Kim et al. (2014) showed that adjunctive or monotherapy quetiapine improved sleep continuity in patients with unipolar or bipolar disorder. A PSG study with ziprasidone augmentation in bipolar patients with an acute depressive episode improved sleep induction, sleep continuity and sleep architecture (Baskaran et al., 2013). Overall, these results indicate a potential beneficial effect on sleep of dopamine-serotonin antagonists in patients prescribed them for a labelled indication.

In patients with insomnia, a small open study of quetiapine (25 mg in most patients) for six weeks (Wiegand et al., 2008) showed improvements in sleep, with transient adverse effects of morning hangover and dry mouth. A double-blind, placebo-controlled study which investigated the efficacy of quetiapine (25 mg) in primary insomnia (Tassniyom et al., 2010) had a small sample size (n=13) and subjective improvements in sleep were not significant.

Side effects are well documented, and include weight gain, metabolic syndrome, extrapyramidal symptoms and risk of tardive dyskinesia. There are some case reports of abuse of quetiapine in inpatients and prisoners (Sansone and Sansone, 2010). A review of quetiapine for use in insomnia (Anderson and Vande Griend, 2014), concluded that its benefit in the treatment of insomnia has not been

---

**Recommendations**

- Use drugs according to a knowledge of pharmacology (A).
- Consider drugs for depression when there is co-existent mood disorder (A).
- Beware toxicity of TCAs in overdose even when low unit doses prescribed (A).

**Drugs for psychosis for treatment of insomnia**

<table>
<thead>
<tr>
<th>What is known about use of drugs for psychosis in treatment of insomnia:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Dopamine-serotonin antagonists particularly olanzapine and quetiapine improve sleep in healthy participants (Ib).</td>
</tr>
<tr>
<td>• Quetiapine, ziprasidone and lurasidone improve sleep in models of transient insomnia (Ib).</td>
</tr>
<tr>
<td>• When used on label, clozapine, olanzapine, quetiapine, risperidone and ziprasidone improve sleep continuity in schizophrenia, unipolar and bipolar disorder (I).</td>
</tr>
<tr>
<td>• Minor improvements in sleep in primary insomnia are seen after quetiapine (IIb).</td>
</tr>
<tr>
<td>• Side effects are common because of the broad pharmacological actions of these drugs (I).</td>
</tr>
</tbody>
</table>

**What is not known:**

- How drugs for psychosis compare with approved drugs for insomnia?
proven to outweigh potential risks, even in patients with a comorbid labelled indication for quetiapine. An American Academy of Sleep Medicine clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults also concluded that quetiapine was not indicated for use in insomnia (Sateia et al., 2017).

**Recommendations**

Side effects are common because of the pharmacological actions of drugs for psychosis and there are a few reports of abuse.

Together these indicate no indication for use as first-line treatment (D).

**Antihistamines (H1 antagonists).** Antihistamines are sedating and are sold as ‘over the counter’ (OTC) sleeping medications. There is only limited evidence that these older non-selective antihistamines work, although some modest benefits have been reported after two weeks dosing with diphenhydramine in mild insomnia (Morin et al., 2005b). More profound acute effects on sleep have been reported for both promethazine and hydroxyzine in healthy volunteers (Adam and Oswald, 1986; Alford et al., 1992) but the latter is not available OTC, and both have quite long durations of action so are likely to cause hangover effects.

Antihistamines are sometimes used in alleviation of insomnia in drug and alcohol withdrawal where traditional hypnotics are less suitable due to the risk of cross-dependence, although there are no controlled trials in this setting. These drugs have anticholinergic side effects, making them dangerous in overdose.

The selective antihistamine (low-dose) doxepin 1–6 mg has been shown to be effective in insomnia in adults and the elderly, with few residual effects, and is approved in the USA but not in Europe. It has been shown to particularly reduce awakenings in the latter part of the night. Another selective agent, low-dose esmirtazapine, is currently undergoing evaluation.

**Recommendations**

The selective antihistamine doxepin (very low dose) is effective in insomnia (A).

Non-selective histamine antagonists have a limited role in psychiatric and primary care practice for the management of insomnia (D).

**Circadian rhythm disorders**

Daily rhythms of sleeping and waking are controlled by a variety of brain mechanisms, the most prominent of these being the circadian process (the ‘body clock’ signalling time for sleep) and the homeostatic process (a build-up of sleep pressure during the hours of wakefulness). These two processes work together to consolidate sleep and wakefulness (Diik and von Schantz, 2005).

Circadian rhythm is a roughly 24-hour cycle in the physiological processes of living beings. It is internally generated, although it can be modulated by external cues (zeitgebers) such as sunlight, and feeding and drinking, and in humans by daily routines of work, exercise etc. Circadian rhythms are controlled by a brain pacemaker in the SCN of the anterior hypothalamus, which has a direct input from the retina signalling light levels. Most body systems, not only sleeping and waking, are to some degree modulated by input from this circadian pacemaker.

The innate frequency of the circadian clock in humans is slightly longer than 24 h, and synchronisation with the external 24-hour physical environment and day-to-day activities requires daily adjustments to the internal clock. The light-dark cycle is the strongest synchronising agent for the circadian system. In humans, light exposure in the evening produces delays, and in the early morning produces advances. The SCN also receives internal signals from the pineal gland, via the nocturnal release of melatonin. Endogenous melatonin release begins to increase 2–3 hours before sleep onset, and peaks in the middle of the night. Exogenous melatonin given during the early morning delays the timing of circadian rhythms and, given during the early evening, induces advances in this timing, which contrasts with the effects of light.

There are differences within humans in their preference for sleep times (chronotype). Some people preferring to rise early and are at their best in the morning (‘morningness’, or ‘larks’) and those who rise later and are at their peak later in the day (‘eveningness’, or ‘owls’) These preferences be determined in part by genetics. Children are early chronotypes and become progressively later (delaying) as they grow older, reaching a maximum in their ‘lateness’ at around the age of 20 years. After 20 years, they become earlier again (advancing) with increasing age. Young women reach their maximum in lateness earlier than men; men continue to delay their sleep until around the age of 21 years and remain later chronotypes for most of their adulthood (Roenneburg et al., 2004). This gender difference disappears at around the age of 50 years, which coincides with the average age of menopause.

Circadian rhythm sleep-wake disorders (CRSWDs) occur when there is an alteration of the endogenous circadian system or a misalignment between the endogenous circadian rhythm and the sleep-wake schedule required by the physical environment or social or work timetable. This results in insomnia when they are needing to sleep, and sleepiness when alertness is required, causing significant distress and impairment of function.

There are six CRSWDs defined in ICSD:

Jet Lag Disorder occurs when the circadian clock has a temporary misalignment after rapid transition across time zones. Symptoms of insomnia, daytime sleepiness and physical discomfort normally disappear once there is exposure to zeitgebers in the new environment, within a length of time proportional to the number of time zones crossed. Thus after an eastbound trip from the USA west coast the circadian clock might take several days to settle into the UK routine. This condition tends not to present to health professionals for treatment, although it is likely to have some destabilising impact on conditions such as bipolar disorder.

Delayed Sleep Wake Phase Disorder (DSWPD) affects 2–8% of the population and is most prevalent in young adults. There is usually difficulty falling asleep before 02:00–03:00 (sometimes later), and on days without work/school/college the preferred wake time is after 10:00, resulting in sleep-onset insomnia and difficulty waking up in the morning on days when an early bedtime for an early start time is necessary. There is a high incidence of comorbidity with psychiatric disorder in those with DSWPD with up to 60% of people having a diagnosis of depression, substance abuse, or anxiety (Abe et al., 2011; Murray et al., 2017; Reid et al., 2012).

Advanced Sleep Wake Phase Disorder (ASWPD) is much rarer, with reports of an average sleep onset from 18:00–21:00 and
Treating circadian rhythm disorders

Diagnosis of circadian rhythm disorders

Assessment of these disorders involves interview, sleep diaries (from parents/carers if necessary) and actigraphy for 14 days. In the case of DSWPD and ASWPD it is recommended to give the morningness-eveningness questionnaire (Horne and Ostberg, 1976).

What is known:
- Melatonin is effective in jet lag disorder (1a), delayed sleep phase syndrome (1b) and non-24-hour sleep rhythm disorder (IIa).
- Light therapy is effective in delayed sleep phase syndrome (III).

What is not known:
- What are the best efficacy measures – subjective or objective?
- Is there a need to distinguish between adults and adolescents in DSWPD since sleep times are somewhat delayed in normal adolescence?
- Is there a need to distinguish between sighted and blind individuals?
- Is melatonin or light therapy more effective for DSWPD?

Current understanding of circadian rhythms and sleep physiology provides a strong theoretical basis for the use of melatonin in some, but not all CRDs. Empirical evidence for efficacy is strong in some CRDs, but weak or absent in others. Melatonin agonists may be promising in the treatment of CRDs, e.g. non-24-hour SWRD (Lockley et al., 2015), but there remains a need for RCTs in well-characterised CRD populations.

There is solid evidence to support the use of melatonin in jet lag (Spiegelhalder et al., 2017) but (immediate release) melatonin has to be taken near desired bedtime otherwise there may undesired daytime sleepiness. An evidence-based strategy for minimising jetlag which includes strategic scheduling of sleep combined with melatonin is given by Sack (Sack, 2010).

In DSWPD, there is both a theoretical and an empirical basis for use of melatonin, which is effective in practice, shown in two systematic reviews (MacMahon et al., 2005; Sack et al., 2007a); however studies in these reviews vary in the physiological and subjective outcomes measured. Direct comparison with other therapies such as timed-light exposure, for which there is a little evidence of efficacy (see below), or chronotherapy, for which there are no controlled trials, has not been reported. In one trial, efficacy of melatonin combined with sleep scheduling was compared to sleep scheduling alone and found to be effective (Sletten et al., 2018).

In non-24-hour sleep rhythm disorder, in sighted individuals, case reports (n=5) suggest a positive benefit of melatonin. The evidence in blind people is more compelling where case reports and two small, single-blind placebo-controlled studies are positive (Sack et al., 2007a; Skene and Arendt, 2007; Skene et al., 1999). Two RCTs of the selective melatonin agonist tasimelteon in totally blind individuals showed a positive effect on entrainment (Lockley et al., 2015).

There is no evidence of the efficacy of melatonin in irregular sleep wake rhythm, or in shift work disorder, although there have been some reports of use in shift workers with varying results (Sack et al., 2007b).

Bright-light therapy has been used effectively in delayed sleep phase syndrome (Shirani and St Louis, 2009). Exposure to bright light of 2500 lux for two hours in the early morning, combined with light restriction after 16:00 (dark goggles) is an effective treatment for delayed sleep phase syndrome and a light mask offering exposure to gradually increasing light intensity through closed eyelids over the last four hours of habitual sleep time has been shown to be effective in these patients.

In the elderly patient with dementia with an irregular sleep wake disorder there is a little evidence to support the use of bright-light therapy in combination with behavioural interventions, but the use of melatonin is discouraged (Auger et al., 2015).

Recommendations

Clinical assessment is essential in delayed sleep wake phase disorder, non-24-hour sleep rhythm disorder [A].

Melatonin may be useful in delayed sleep wake phase disorder, non-24-hour sleep rhythm disorder in non-sighted individuals and jet lag disorder [B].

Other approaches such as behavioural regimes and scheduled light exposure (in sighted individuals) can also be used [B/C].

Because of the necessity for careful timing of interventions, patients with these disorders need to be treated in specialised sleep disorders centres (D).
Parasomnias

Parasomnias are unusual episodes or behaviours occurring during sleep which disturb the patient or others and this document addresses those that cause significant distress and therefore present for treatment. Violent or unusual night-time attacks may arise from deep non-REM sleep (night terrors and sleepwalking) or from REM sleep [sleep paralysis, severe recurrent nightmares, REM behaviour disorder (RBD)] and treatments depend on which disorder is present.

Night terrors (also called sleep terrors) are recurrent episodes of abrupt awakening from deep non-REM sleep, usually in first third of night, usually with a scream and signs of intense fear and autonomic arousal, and the patient is unresponsive to comforting. They may sit up in bed and sometimes engage in automatic behaviour associated with fear and escape. There is usually no detailed recall, and if the patient wakes from a terror (not common), there is confusion and disorientation and only a vague memory of fear. Night terrors are common in children with 30–40% having at least one episode and repeated episodes in about 5%. The peak age for these is at about 2–7 years with a gradual diminution up to early adolescence (Stallman et al., 2018). In some cases they persist into adult life; the prevalence in adults is unknown. Almost all adult patients have had night terrors or sleepwalking as a child (Crisp, 1996) there is a strong genetic component (Nguyen et al., 2008), and night terrors and sleepwalking in the same patient is fairly common. Sleepwalking alone probably has 15–20% lifetime prevalence. The main symptom is of automatic behaviour at night with the sufferer unresponsive to surroundings and other people. The behaviour is most commonly walking around, but can include other behaviours which are highly familiar to the subject such as dressing, washing, making tea, arranging objects in the house. Some cases of sleepwalking seem related to use of certain drugs e.g. alcohol and hypnotics, especially zolpidem and triazolam, opiates (possibly related to sleep-disordered breathing) (Pressman et al., 2007), or other sleep disorders such as sleep apnoea. It is rare for affected individuals to present for treatment, except if they have injured themselves or a partner, have put themselves into potential danger, or have excessive daytime fatigue because of night time disturbance. Another reason for presentation is anxiety and disruption of sleep of partner, family or housemates.

Sleep paralysis, nightmares and REM sleep behaviour disorder (RBD) are disorders arising from REM sleep. Sleep paralysis and nightmares are recalled by the patient. REM behaviour episodes are sometimes recalled but more often only apparent to the bed partner.

Sleep paralysis is a brief state of involuntary immobility usually occurring on waking from a night’s sleep or a nap (more rarely at sleep onset). It is often accompanied by dream imagery, sometimes of a frightening kind, and sometimes a feeling of chest tightness. It is attributed to waking abruptly from REM sleep episode with the REM atonia persisting briefly. It appears to be more common in those with narcolepsy, and in those with irregular sleep-wake routine and after drinking alcohol.

RBD is a disorder first described in the late 1980s with violent complex behaviour at night. There are two sleep abnormalities: lack of atonia during REM sleep (which can be quantified using video-polysomnography), and increased vividness and/or nasty content of dreams. The violent behaviour is described as ‘acting out of dreams’, made possible by the lack of the normal muscle paralysis in REM sleep causes injury to self or bed partner in up to 70% of patients. Its incidence is estimated at 0.5–1% of those over 55 years), occurs in older people with a steady rise after 55 years and has a male preponderance in older patients. It is now well recognised as the most robust prodromal, non-motor symptom of a subsequent neurodegeneration, typically an alpha synucleinopathy. Several cohorts under long term follow-up have shown that 50% at five years and 91% at 15 years will have developed another neurodegenerative problem. It is often associated with Parkinson’s disease (PD) (it is seen in up to 50% of PD patients), Lewy body dementia (~70%), multiple system atrophy (>90%). RBD often precedes other symptoms of neurodegeneration by several years (Iranzo et al., 2014).

Diagnosis of parasomnias

Assessment of parasomnia may be possible with a detailed history from patient or witness, but in general for adequate diagnosis, referral to a specialist sleep centre for polysomnography and video recording may be necessary especially for RBD where loss of REM atonia is seen.

Treatment of parasomnias

There is little high-level evidence for treatments in these disorders. There are no controlled trials of treatment of non-REM parasomnias in adults (Harris and Grunstein, 2009). Priorities are to minimise possible trigger factors such as noise, frightening films, caffeine, alcohol or meals late at night; and to make sure there is a stable and adequate sleep-wake schedule. It is important to safeguard against harm to the patient, such as by locking windows, bolting doors, or sleeping on the ground floor, and safety of the bed partner or nearby children also requires attention.

Drug treatment decisions should be based on the frequency and severity of events. Clonazepam in doses up to 3 mg per night has been reported to be effective (case series, n=69) (Schenck and Mahowald, 1996). Smaller case series have reported good effects of paroxetine (Wilson et al., 1997) and imipramine (Cooper, 1987) (both effective immediately) and there are several case series of hypnotherapy in sleepwalkers (Becker PM, 2015). A randomised controlled study of three weeks’ treatment with 5-hydroxytryptophan in children found evidence of efficacy at six-month follow-up (Bruni et al., 2004).

For nightmares, psychological treatments are effective and these focus on exposure – writing down dreams – or guided imagery, pleasant images, and ‘changing the ending’ (Burgess et al., 1998; Hansen et al., 2013; Krakow et al., 2001). There is good evidence of beneficial effects of the alpha-1 adrenergic blocker prazosin in reducing nightmares related to PTSD in both military and civilian settings and in the paediatric population (Keesin et al., 2017; Nadorff et al., 2014). Nightmares have been reported to be triggered or worsened by many drug treatments including cholinesterase inhibitors, beta-blockers, SSRIs (especially paroxetine) levodopa, and following withdrawal from drugs for depression.
For RBD, all data on treatment comes from retrospective case notes review and for melatonin, a single, small crossover randomised trial. There are no prospective or controlled studies of clonazepam for RBD, but large case series suggest a good effect when used at doses between 1–4 mg (Aurora et al., 2010; Boeve et al., 2004) in reducing number of episodes and injury during them. Dose-limiting side effects are common in those with dementia, disorders of gait or balance, or comorbid OSAS (Anderson and Schneerson, 2009). Beneficial effects have been reported for melatonin 3–12 mg but with fewer adverse events. A single, small RCT has shown benefit for melatonin including in quantitative measure of REM atonia (Kunz and Mahlberg, 2010). Single case studies and small series have reported beneficial effects of clonidine (Nash et al., 2003), donepezil (Massironi et al., 2003), and sodium oxybate (Kosky et al., 2008).

Drugs which can worsen RBD or provoke its symptoms include SRIs, venlafaxine, mirtazapine, bisoprolol and tramadol (Gagnon et al., 2006).

Special populations

Sleep disorders in women: effects of menopause and pregnancy

Menopause. Insomnia increases as women approach and pass through the menopause (Bixler et al., 2009; Kuh et al., 1997; Owens and Matthews, 1998). Post-menopausal women have a longer sleep latency and decreased slow-wave sleep. This is due to a variety of reasons – climacteric symptoms e.g. hot flushes due to hormonal changes and psychiatric disorders are most often cited. Hormone therapy appears to protect women from these changes (Bixler et al., 2009).

CBT has been shown to be effective in insomnia in this group, with long lasting benefits up to six months post-treatment (McCurry et al., 2016). There are modest benefits from some but not all studies of pharmacotherapy with SRIs including escitalopram, citalopram and venlafaxine although short duration of follow-up limits the conclusions that can be drawn from the studies (Ensrud et al., 2012; Davari-Tahna et al., 2016).

Post-menopause, there is also a rise in the incidence of sleep-disordered breathing (Young et al., 2003) (Bixler et al., 2001). Post-menopausal women with sleep-disordered breathing are more likely to complain of depression and insomnia than men with a similar degree of OSAS (Shepertycky et al., 2005).

Recommendations

Clinicians should appreciate that there is a rise in incidence of sleep-disordered breathing after the menopause and that clinical presentation, often including insomnia, in women is different to men (D).

The use of hormone therapy should involve informed individualised treatment of symptoms, looking at risks and benefits in light of recent studies (A).

Follow recommendations for insomnia in other sections (A).

Pregnancy. Many women report poor sleep during pregnancy with the reasons varying depending on the trimester. In the first trimester, nausea, backache and urinary frequency can cause sleep disturbance. The second trimester tends to be easier but foetal movements and heartburn may be troublesome. By the third trimester, sleep is more disturbed with complaints again of urinary frequency, backache in addition to cramps, itching and unpleasant dreams. Most women fall asleep fairly easily but wake more frequently (Sedov et al., 2018).

If a patient suffers from intractable insomnia and a pharmacological agent is required, it is helpful to note that zolpidem and diphenhydramine are in FDA class B (foetal harm possible, but unlikely; no evidence of foetal harm in animal studies) (for review see (Pien and Schwab, 2004). However, non-selective histamine antagonists such as diphenhydramine can exacerbate restless legs syndrome (RLS) and have anticholinergic actions. Zolpidem may be preferable as it is short-acting and does not have anticholinergic side effects. The hypnotics temazepam and zopiclone have not been associated with any increase in congenital malformations (Ban et al., 2014).

RLS is common in pregnancy, with a prevalence between 15–25%, peaking in the third trimester with improvement in the last two weeks and often resolving post-partum. It is sometimes associated with anaemia (Hubner et al., 2013; Neau et al., 2010). Iron replacement is safe and may be effective based on small case series, with carbidopa/levodopa or clonazepam only recommended in severe and refractory cases (Picchietti et al., 2015).

Snoring and sleep disordered breathing, especially in obese subjects, is increasingly recognised, is associated with worse foetal outcomes and affects up to 8% of women by the third trimester. (O’Brien et al., 2014).

Recommendations

Good sleep hygiene and lifestyle (D).

Manage general pregnancy associated complaints e.g. decrease fluid intake, pillow support (D).

The effects of CBT in pregnancy have only been assessed in one small open-label study, but this approach seems sensible (B).

Recognise RLS by careful history and investigations if necessary.

○ Dopamine agonists are contraindicated (FDA category C or greater).
○ Iron supplementation has been shown to be effective in RLS. Supplementation is suggested even if levels are not low (D).
○ Keep caffeine low as it can exacerbate RLS (D).
○ Mild-moderate exercise in the early evening, stretching, massage (D).

If patient suffers from intractable insomnia and a pharmacological agent is required, zolpidem or zopiclone should be used short-term after discussion on potential risks and benefits (D).
### Treatment of insomnia in older adults

**What is known about treatment of insomnia in older adults:**
- CBTi is effective in older adults and is associated with minimal side effects (Ia).
- Zolpidem, suvorexant and doxepin improve global and sleep outcomes (Ib).
- Prolonged release melatonin given for three weeks improves sleep onset latency and sleep quality in patients over 55 years (Ib).
- Drugs with sedative effects increase the risk of falls in older adults (III).
- Benzodiazepine hypnotics have an unfavourable risk/benefit ratio (B).
- Insomnia increases the risk of falls and fractures in nursing homes independently of medication (III).

**What is not known:**

Is there an effective treatment for sleeplessness in older adults with dementia?

Insomnia in elderly patients often responds well to CBTi (see psychological treatment section above). Meta-analyses comparing CBT outcomes in older adults (55 years plus), have reported moderate to large effect sizes, whether or not insomnia is comorbid with other disorders (Alessi and Vitiello, 2015).

A meta-analysis (Glass et al., 2005) concluded that benzodiazepine hypnotics had an unfavourable risk/benefit ratio in elderly patients, but the different methods of collection and categorisation of drug-related side effects in the studies included makes them difficult to interpret. Individual randomised controlled studies with short-acting Z drugs show little evidence of adverse effects, particularly cognitive side effects in the morning. However if a patient needs to rise within a few hours after taking a benzodiazepine agonist drug there may be undesired effects on motor control. Falls are increased after sedatives and hypnotics, drugs for depression or psychosis, benzodiazepines, nonsteroidal anti-inflammatory drugs and calcium channel antagonists (Woolcott et al., 2009) but this study did not specify daytime/night-time use. There is a 2.5-fold risk of falls in hospital after zolpidem (Rhalimi et al., 2009), but in nursing homes the situation may be different; in a large study (Avidan et al., 2005) insomnia itself, but not hypnotic use, was associated with an increase in falls and hip fractures. Therefore the development of sleep-promoting drugs without motor side effects has been welcomed.

Prolonged release melatonin has been shown to reduce sleep onset latency and increase subjective sleep quality in patients over 55 years (Lemoine et al., 2007; Wade et al., 2007, 2011); its effects are modest but it has no known motor side effects.

The antihistamine drug doxepin (in very low dose 3 mg, see above) has been found effective in insomnia in the older patient, in particular decreasing awakenings in the latter half of the night without daytime effects (Lankford et al., 2012; Krystal et al., 2013).

A Cochrane review, looking at pharmacotherapies for sleep disturbances in dementia (McCleery et al., 2016) found a lack of evidence to help guide drug treatment of sleep problems in dementia. Few RCTs have been conducted. There is some evidence to support the use of low dose trazodone (Camargos, 2014). This is an area with a high need for pragmatic trials, particularly of those drugs that are in common clinical use for sleep problems in dementia.

### Recommendations

- CBTi is effective and should be offered as a first line treatment where available (A).
- When a hypnotic is indicated in patients over 55 years prolonged release melatonin should be tried first (B).
- If a GABA-A hypnotic is used then a shorter half-life will minimise unwanted hangover effects (A).

### Sleep problems in children

**What is known:**
- Most sleep settling and maintenance problems in childhood respond well to behavioural treatments (I).
- Melatonin reduces long sleep latency (following appropriate behavioural interventions) in children with sleep onset insomnia or delayed sleep phase syndrome and learning difficulties, autism and attention deficit hyperactivity disorder (ADHD) (II).

**What is not known:**

- What are the long-term effects of melatonin?

Sleep problems are commonly associated with certain genetic and neuro-developmental problems seen in childhood including ADHD, autism, learning difficulties and epilepsy. Training and awareness of paediatric sleep disorders is poor and accurate diagnoses and hence appropriate treatments are often delayed. Settling and sleep maintenance problems may be exacerbated by a sleep disorder such as obstructive sleep apnoea or RLS.

Evidence from systematic review suggests that most sleep disorders in childhood respond well to behavioural treatments (Mindell et al., 2006). Appropriate sleep hygiene measures and more specific techniques of extinction, or graduated extinction, are all more effective than placebo at improving sleep and reducing the number of weekly night wakings in otherwise healthy children who regularly wake up in the night (Ramchandani et al., 2000). These interventions hold for both typically developing children and children with learning difficulties and sleep problems. These interventions may not change sleep parameters in the child, but instead improve outcomes related to impact on parents and other carers.

The sedative side effects of antihistamines may speed up behavioural programmes over short periods (France et al., 1991) but seem not to work without behavioural interventions; in a placebo-controlled double-blind trial in infants aged 6–27 months the same authors found no significant effect of 15 mg or 30 mg trimepazine tartrate, and concluded that it is not recommended as a pharmacological treatment for infant sleep disturbance unless as an adjunct to a behavioural therapy program (France et al., 1999). Clinically the short term use of an H1 blocker for transient or extreme insomnia is frequently employed: however, tolerance can develop quickly and some children can experience dramatic and paradoxical over-arousal. The TIRED RCT specifically investigated the use of diphenhydramine in infants aged from 6–15 months and found it was no more effective than placebo in reducing night-time awakening (Merenstein et al., 2006).

It is important to consider the effects of these medications at neurotransmitter systems other than H1 receptors, particularly in relation to side effects due to anticholinergic or dopamine antagonist action.
The evidence supporting use of melatonin to reduce long sleep latency (following appropriate behavioural interventions) in populations of children with idiopathic sleep onset insomnia (Smits et al., 2003) or delayed sleep phase syndrome and learning difficulties, autism and ADHD (Gringras et al., 2017; Maras et al., 2018; Rossignol and Frye, 2011; van der Heijden et al., 2007) is increasingly robust. There is little clarity in the definition of sleep problems in adults with intellectual disability. This is primarily because it is difficult to obtain subjective measures from the patient who may be unable to communicate verbally or even perceive that they are having a problem. Reports of sleep difficulties tend to be from carers as they struggle to cope with issues which only seem to be exacerbated when they, and the person they care for, experience sleep disturbance. There is a compelling need to develop a more accurate, standardised measure of sleep for this population (Meltzer and Mindell, 2014), to obtain essential information about prevalence.

Difficulties in assessing sleep disorders include diagnostic overshadowing, where behaviours such as daytime sleepiness, inattention and challenging behaviour are regarded as symptomatic of the intellectual disability as opposed to being indicative of a sleep disorder. In these circumstances therefore, clinicians may fail to consider the possibility of sleep disturbance and thus neglect to undertake more detailed investigations.

The situation is further compounded by the fact that health and behavioural problems can increase as sleep problems develop. For example, the inability to problem solve combined with daytime somnolence exacerbates cognitive processing problems in those already compromised intellectually (Carr et al., 2003; Symons et al., 2000).

Within this population there are additional high-risk groups including those with co-morbidities such as Down syndrome where people may present with sleep related breathing disorders, or Smith-Magenis syndrome where melatonin rhythm is inverted. In general, there are a wide range of precipitating and perpetuating factors to consider including maladaptive coping strategies, the impact of medication e.g. drugs used in psychosis, depression, epilepsy including side-effects and the impact of polypharmacy on sleep and daytime functioning. For those in institutional or residential living environments the environment itself may contribute to disturbed or inconsistent sleep patterns, as other patients/residents wake others up or staff shift patterns determine wake/sleep times rather the individuals themselves.

Assessment. Sound clinical assessment should elicit any aetiological or exacerbating factors which can be reversed. This may be best undertaken by direct observation initially. Carers should be supported to keep a structured 24-hour record of sleep pattern and behaviour. Actigraphy or EEG may be useful when a sleep disorder other than insomnia or settling difficulties is suspected, but clinicians should be aware that the recording equipment may not be tolerated by people with more moderate to severe levels of intellectual disability. The possibility of a CRD should also be excluded in individuals with additional visual impairment.

Treatment considerations. There is a varying degree of evidence for treatments of sleep difficulties in this heterogeneous population. Systematic review (van de Wouw et al., 2012) used SIGN 50 methodology but no statistical analysis in 50 studies using behavioural interventions in adults with intellectual disabilities. They concluded there was some indication of the effectiveness of behavioural interventions. In addition, they reported that in some cases sleep problems were associated with challenging behaviour and medication.

The relatively small number of controlled studies in this area give support to parental/carer education and modifying environmental factors (Montgomery et al., 2004). Behavioural regimes such as chronotherapy, bedtime fading, extinction, distancing/desensitisation and sleep-wake scheduling (Wiggs and France,
2000; Gunning and Espie, 2003) may also prove beneficial. The use of light therapy has been described (Short and Carpenter, 1998).

There is little evidence for effectiveness of sleep-promoting drugs, apart from melatonin. A meta-analysis (Braam et al., 2009) indicated that melatonin (1–9 mg) decreases sleep latency and number of wakens per night, and increases total sleep time in individuals with intellectual disabilities. There were few adverse events in the relatively short-term studies included, however long term safety requires further research.

Recommendations

Clinical assessment should describe sleep disturbance and elicit aetiological and exacerbating factors (A).

Environmental, behavioural and educational approaches should be used first line (A).

Melatonin is effective in improving sleep (A).

Treatment should be planned within a capacity/best interests framework (D).

Acknowledgements

Although the first author prepared the document for publication, all authors contributed equally to the consensus.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References


### Appendix 1

Two-item version of the Sleep Condition Indicator (SCI) 02 (Luik et al. (2019) Screening for insomnia in primary care: Using a two-item version of the Sleep Condition Indicator. *Br J Gen Pract* 69: 79–80.)

<table>
<thead>
<tr>
<th>Item</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thinking about the past month, to what extent has poor sleep ...</strong></td>
<td></td>
</tr>
<tr>
<td>1. ... troubled you in general</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td><strong>Thinking about a typical night in the last month ...</strong></td>
<td></td>
</tr>
<tr>
<td>2. ... how many nights a week do you have a problem with your sleep?</td>
<td>0–1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>5–7</td>
</tr>
</tbody>
</table>

Scoring instructions: add the item scores to obtain the SCI total (minimum 0, maximum 8). A lower score means better sleep.